Flex Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Flex Pharma and buy or sell other stocks, ETFs, and their options commission-free!

About FLKS

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. 

CEO
Frederick E. Pierce, II
CEOFrederick E. Pierce, II
Employees
Employees
Headquarters
Houston, Texas
HeadquartersHouston, Texas
Founded
Founded
Employees
Employees

FLKS Key Statistics

Market cap
4.72M
Market cap4.72M
Price-Earnings ratio
-0.02
Price-Earnings ratio-0.02
Dividend yield
Dividend yield
Average volume
261.77K
Average volume261.77K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$34.65
52 Week high$34.65
52 Week low
$0.5148
52 Week low$0.5148

Stock Snapshot

With a market cap of 4.72M, Flex Pharma(FLKS) trades at $6.68. The stock has a price-to-earnings ratio of -0.02.

On 2026-02-15, Flex Pharma(FLKS) stock opened at —, reached a high of —, and a low of —.

Flex Pharma(FLKS) shares are trading with a volume of 0, against a daily average of 261.77K.

In the last year, Flex Pharma(FLKS) shares hit a 52-week high of $34.65 and a 52-week low of $0.51.

In the last year, Flex Pharma(FLKS) shares hit a 52-week high of $34.65 and a 52-week low of $0.51.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.